Novo Nordisk announces changes in Executive Management

Core Viewpoint - Novo Nordisk announced significant changes in its Executive Management team, effective April 3, 2025, following the departure of Camilla Sylvest after 28 years with the company [1]. Group 1: Executive Management Changes - Camilla Sylvest, after a 28-year career with Novo Nordisk, including seven years as executive vice president of Commercial Strategy & Corporate Affairs, has decided to leave the company [1]. - Ludovic Helfgott, previously executive vice president of Rare Disease, will take on the role of executive vice president for Product & Portfolio Strategy, overseeing commercial strategy, medical affairs, and business development across all therapy areas [1]. - Thilde Hummel Bøgebjerg has been promoted to executive vice president of Quality, IT & Environmental Affairs, having spent 18 years with Novo Nordisk in various leadership roles [2]. - Tania Sabroe, currently executive vice president of People & Organisation, will also assume responsibility for Global Communication [3]. Group 2: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focusing on chronic diseases, particularly diabetes [4]. - The company employs approximately 76,300 people across 80 countries and markets its products in around 170 countries [4]. - Novo Nordisk's B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange [4].